Member Info for RayPointer

Yes, Modi1 with checkpoints is looking good, albeit very early days

I don't think Cohort 2 numbers will concern Scancell.

The next trial, already in the planning by Scancell, will be either SCIB1 with the 2 CPIs or iSCIB1+ with the 2 CPIs.

Miavoce

"Given we'll have at least 33 patients in cohort 3 at 25 weeks by end May I would hope that we get an update on iSCIB1 in H1 (given that for cohort 1 we have just had an update for 25 patients at 25 weeks)."

Agreed, it is likely that the promised first report of iSCIB1+ in H1 2025 still stands. So, likely we will get 3 reports in 2025.

1) interim iSCIBi+ report (based loosely on the same SCIB1 patient numbers just reported) H1

2) Full SCIB1 data (all patients reached the 25 week scan) H1

3) Full iSCIB1 data (all patients reached the 25 week scan) H2

Kennedy is not exactly a loyal follower of Trump.

I suspect Trump is giving him enough rope to hang himself.

Trump will use the first indication that Kennedy is not an ardent admirer of the great man to fire him.

🤣

Yes, thanks WTP.

Scancell may be hobnobbing with the big boys now

I wonder if scinv is attending

Great find ciaskin

If you want to apply for a free ticket:

https://www.ticketsource.co.uk/university-of-liverpool-lhnc/lhnc-webinar-series-research-education-development-lectures-2024-professor-christian-ottensmeier/e-odozab

Am I missing something, but didn't CT state:

"On paper they could destroy Merck/Moderna, Biontech, IObio trials"

whereas Ivy, in his criticism, missed out the word "trials"

CW - the list shows 2 columns of ISINs and company names.

Palo Alto is the company before Scancell on the list. It's as simple as that.

Remember T Cell responses are about the activation and proliferation of T Cells and not the tumour response data that we are eagerly awaiting in the Scope trial.

If the T Cell response from SCIB1 is 87%, it possibly also augers well for the Modi1 results in combination with CPIs. Previously Scancell announced 100% T Cell response in the early Modi1 monotherapy data. Fingers crossed, and as already mentioned by Lindy, the renal cancer plus 2 CPIs Modi1 cohort could also impress the pharma world.

"Much ado about nothing" methinks

Sorry emptyend

My understanding was that Lindy would report when they have 27 responders (see first question at about 33 mins 15 secs into the AGM recording).

I might be wrong since part of Lindy's answer was unclear.

I think we've already had indications of positive news.

Now it's just a case of when we get to 27 responders.

The jury will now deliberate on the sanity of the prosecuting counsel 😂

I agree.

I think Lindy was just extrapolating current results to how they will probably pan out to year end.

Thanks for confirming that miavoce.

Miavoce

It's funny you should have posted this.

I was thinking in a very similar manner.

Did Lindy say whether the Q4 data would be based on the 1st scan after dosing or the 2nd?

scinv should be able to answer that 😂

If it is based solely on patients with at least 2 scans then the results will be even better, but I suspect it will be based on patients with at least 1 scan.

If only there were a Nobel Prize for being pedantic.....

Konar

What you say is possible.

70% (the endpoint) of 43 is 30 (rounded down from 30.1) .

If what you say is true, perhaps they already have 30 out of 36 responders (83%)